Malignant Soft Tissue Neoplasm — Trials

Malignant Soft Tissue Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 341
Recruiting: 190
Ph III recruiting: 14
Growth YoY: −18.5%
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (200)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03994627	Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma	approved for marketing	—	—	Eli Lilly and CompanyINDUSTRY	11	Dec 16, 2024	clinicaltrials
NCT03817515	Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation	approved for marketing	—	—	Aadi Bioscience, Inc.INDUSTRY	0	Mar 16, 2022